We are live on ! Find out more
VKTX icon

Viking Therapeutics

137 hedge funds and large institutions have $185M invested in Viking Therapeutics in 2020 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

203% more call options, than puts

Call options by funds: $7.19M | Put options by funds: $2.37M

5% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 39

0.59% less ownership

Funds ownership: 55.05%54.46% (-0.59%)

4% less funds holding

Funds holding: 143137 (-6)

13% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 23

42% less capital invested

Capital invested by funds: $319M → $185M (-$134M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
137
Holders Change
-6
Holders Change %
-4.2%
% of All Funds
3.02%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
20
Increased
41
Reduced
39
Closed
23
Calls
$7.19M
Puts
$2.37M
Net Calls
+$4.82M
Net Calls Change
-$193K
Name Holding Trade Value Shares
Change
Change in
Stake
TRCT
151
Tower Research Capital (TRC)
New York
-$19.1K -3,111 -97%
PA
152
Parallel Advisors
California
-$13K -1,568 Closed
NFG
153
Next Financial Group
Texas
-$9K -1,075 Closed
SPIA
154
Steward Partners Investment Advisory
New York
-$4K -550 Closed
QT
155
Quantbot Technologies
New York
-$1K -200 Closed
EWM
156
Edge Wealth Management
New York
-$1K -100 Closed
Northwestern Mutual Wealth Management
157
Northwestern Mutual Wealth Management
Wisconsin
+$357 +58 New

VKTX Hedge Fund Activity: Q1 2020 in Review

137 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2020, worth a combined $185M — down 42% from $319M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of VKTX and 20 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 41 added.

The largest buyer was Aviva, opening a new position worth an estimated $3.66M. The largest seller was American Century Companies, exiting entirely with an estimated $4.61M sold.

  • 137 institutional investors held Viking Therapeutics (VKTX) as of Q1 2020, down from 143 in Q4 2019.
  • Funds reported $185M of Viking Therapeutics stock for Q1 2020, down 42% quarter-over-quarter.
  • 20 funds opened new Viking Therapeutics positions in Q1 2020 and 23 closed out, a net change of -3 holders.
  • The largest Viking Therapeutics buyer in Q1 2020 was Aviva, an estimated $3.66M added.
  • The largest Viking Therapeutics seller in Q1 2020 was American Century Companies, an estimated $4.61M sold.

Based on aggregated 13F filings for Q1 2020.